This information is for educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's circumstances, local epidemiology, and most current guidelines. Dosages and recommendations may vary and should be confirmed with official drug references and current clinical guidelines.

---

Typhoid Fever

Overview

• Definition: Typhoid fever, also known as enteric fever, is an acute, life-threatening febrile illness caused by the bacterium Salmonella enterica serovar Typhi (S. Typhi). It is characterized by sustained fever, headache, malaise, and often gastrointestinal symptoms. Salmonella enterica serovar Paratyphi A, B, and C cause a similar but often milder illness known as paratyphoid fever, which is clinically indistinguishable from typhoid fever in its early stages.
• Epidemiology:
  • Global Burden: Typhoid fever remains a major public health problem globally, particularly in low- and middle-income countries with inadequate water, sanitation, and hygiene (WASH) infrastructure. The World Health Organization (WHO) estimates 9 to 14 million cases and approximately 110,000 to 146,000 deaths annually worldwide.
  • Transmission: Primarily transmitted through the fecal-oral route, via consumption of food or water contaminated with the feces of an infected person (symptomatic or asymptomatic carrier). Contaminated shellfish, raw fruits/vegetables fertilized with human waste, and unpasteurized milk are common sources.
  • Geographic Distribution: Highly endemic in South Asia, Southeast Asia, Sub-Saharan Africa, and parts of Latin America. Travel to endemic regions is a significant risk factor for individuals from non-endemic areas.
  • Outbreaks: Can occur following natural disasters, disruptions to water supply, or foodborne contamination.
• Classification:
  • Uncomplicated Typhoid Fever: Fever, headache, malaise, and other typical symptoms without severe complications (e.g., intestinal perforation, hemorrhage, encephalopathy).
  • Complicated Typhoid Fever: Presence of severe organ dysfunction or life-threatening complications.
  • Chronic Carrier State: Asymptomatic individuals who continue to excrete S. Typhi in their feces or urine for more than one year after acute infection. This affects 1-5% of untreated or inadequately treated cases, often associated with gallbladder carriage.

Pathophysiology

• Mechanism:
  1. Ingestion: S. Typhi is ingested, usually via contaminated food or water.
  2. Gastric Survival: Survives the acidic environment of the stomach and reaches the small intestine.
  3. Intestinal Invasion: Invades the intestinal mucosa, primarily through M cells (specialized epithelial cells) overlying Peyer's patches in the distal ileum.
  4. Macrophage Uptake: Phagocytosed by macrophages within the Peyer's patches. Unlike other Salmonella serovars that are killed by macrophages, S. Typhi is able to survive and replicate intracellularly within macrophages.
  5. Lymphatic and Systemic Spread: Infected macrophages then disseminate S. Typhi through the lymphatic system to mesenteric lymph nodes, and subsequently enter the bloodstream via the thoracic duct (primary bacteremia).
  6. Reticuloendothelial System Colonization: Bacteria are taken up by cells of the reticuloendothelial system (RES), particularly in the liver, spleen, and bone marrow, where they multiply.
  7. Secondary Bacteremia: After a period of intracellular multiplication (incubation period of 7-14 days, range 3-60 days), a large number of bacteria are released into the bloodstream, leading to secondary bacteremia and the onset of clinical symptoms (fever).
  8. Re-invasion of Gut: S. Typhi can then re-enter the intestinal lumen via the gallbladder (bile) and Peyer's patches, leading to intestinal inflammation, ulceration, and shedding in feces.
  9. Virulence Factors: Key virulence factors include the Vi antigen capsule (enables evasion of immune detection), lipopolysaccharide (LPS, endotoxin, responsible for many symptoms), and Salmonella pathogenicity islands (SPIs) encoding type III secretion systems (TTSS) that inject effector proteins into host cells, modulating cellular functions.
• Risk Factors:
  • Travel to endemic areas.
  • Consumption of contaminated food or water (e.g., street vended foods, unpasteurized dairy products, raw shellfish).
  • Close contact with an acute case or chronic carrier.
  • Inadequate sanitation and hygiene practices (e.g., lack of handwashing).
  • Immunocompromised states (e.g., HIV/AIDS, malignancy, chronic use of immunosuppressants, achlorhydria/antacid use).
  • Gastric acid suppression (e.g., proton pump inhibitors, H2 blockers) reduces the gastric acid barrier.
• Protective Factors:
  • Vaccination: Available typhoid vaccines provide significant protection.
  • Safe Food and Water: Consumption of boiled water, properly cooked food, and avoiding raw or unpeeled fruits/vegetables in endemic areas.
  • Good Personal Hygiene: Frequent and thorough handwashing with soap and water, especially after using the toilet and before preparing or eating food.
  • Improved Sanitation: Access to clean water and adequate sewage systems.

Clinical Presentation

Signs and Symptoms

The clinical presentation of typhoid fever is highly variable and depends on the stage of the illness, the infecting dose, and the host's immune status. The classic "step-ladder" fever pattern may not always be observed.

• Cardinal Features:

  • Prolonged, Sustained Fever: Typically develops gradually, increasing over several days, often reaching 39-40°C (102-104°F) and remaining elevated, with minimal diurnal variation in the first week.
  • Headache: Common and often severe.
  • Malaise and Fatigue: Generalized weakness and tiredness.
  • Anorexia: Loss of appetite.
  • Relative Bradycardia: Pulse rate disproportionately low for the degree of fever (Faget's sign), though not universally present.

• Early Signs (First Week):

  • Gradual Onset Fever: Rising daily.
  • Constitutional Symptoms: Headache, malaise, fatigue, myalgias, arthralgias.
  • Abdominal Discomfort: Vague abdominal pain, tenderness.
  • Gastrointestinal: Often constipation in adults (up to 50%), less commonly mild diarrhea.
  • Non-productive Cough: May be present early.

• Advanced Signs (Second/Third Week - "Typhoid State"):

  • High Sustained Fever: Persists.
  • "Typhoid State": Progressive deterioration of mental status, characterized by apathy, confusion, delirium, stupor, or even coma. This is a severe manifestation.
  • Gastrointestinal:
    • "Pea-soup" Diarrhea: More common in the second/third week, often foul-smelling, sometimes bloody due to intestinal ulceration.
    • Abdominal Distension and Tenderness: Especially in the right lower quadrant.
  • Rose Spots: Faint, salmon-colored, blanching maculopapular rash, typically 2-4 mm in diameter, appearing on the trunk and chest in crops (10-20 lesions). They are transient, lasting 2-5 days, and may be difficult to see on darker skin tones. Present in 5-30% of cases.
  • Hepatosplenomegaly: Enlargement of the liver and spleen.
  • Bronchitis/Pneumonia: Persistent cough or signs of respiratory involvement.

• Atypical Presentations:

  • Afebrile Typhoid: Rare, seen in vaccinated or immunocompromised individuals.
  • Mild Illness: Particularly in partially immune individuals or children.
  • Acute Abdomen: Due to intestinal perforation or hemorrhage.
  • Localized Infections: Osteomyelitis, cholecystitis, meningitis, rarely endocarditis or arthritis without prominent systemic features.
  • "Ambulatory Typhoid": Mild symptoms allowing patients to remain active, posing a risk of community transmission.

Physical Examination

• Inspection:
  • General Appearance: Patient may appear lethargic, obtunded, or toxic in severe cases.
  • Rose Spots: Look for faint, salmon-colored maculopapular rash, typically on the abdomen and chest.
  • Abdominal Distension: May be present.
• Palpation:
  • Abdominal Tenderness: Diffuse, or localized to the right lower quadrant. Guarding and rigidity suggest peritonitis (perforation).
  • Hepatosplenomegaly: Palpable enlargement of the liver and spleen. Liver span may be increased; spleen may be palpable below the left costal margin.
  • Lymphadenopathy: May be mild, generalized.
• Special Tests:
  • Temperature-Pulse Dissociation (Faget's Sign): Relatively slow pulse rate despite high fever. This is suggestive but not pathognomonic and is not always present.

Diagnostic Approach

History Taking

• Key Questions:
  • Fever Characteristics: Onset, pattern, duration, highest temperature recorded.
  • Travel History: Recent (within 1-2 months) travel to endemic regions (South Asia, Southeast Asia, Africa, parts of Latin America).
  • Exposure History:
    • Consumption of potentially contaminated food or water (e.g., street food, untreated water, raw shellfish, unpasteurized dairy).
    • Contact with known typhoid cases or carriers.
    • Poor hygiene practices.
  • Vaccination Status: History of typhoid vaccination and date of last dose.
  • Gastrointestinal Symptoms: Constipation, diarrhea (character, frequency), abdominal pain, nausea, vomiting.
  • Other Systemic Symptoms: Headache, malaise, myalgia, cough, changes in mental status.
  • Medication History: Use of antibiotics or gastric acid suppressants.
  • Past Medical History: Immunocompromised status, gallstones (risk for chronic carriage).
• Red Flags:
  • Signs of Shock: Hypotension, tachycardia, cold clammy skin, altered mental status.
  • Signs of Peritonitis: Severe abdominal pain, rigidity, rebound tenderness, absent bowel sounds (suggesting intestinal perforation).
  • Gastrointestinal Hemorrhage: Hematemesis, melena, or frank blood in stool.
  • Severe Neurological Impairment: Deep stupor, coma, seizures, focal neurological deficits.
  • Persistent Vomiting/Diarrhea: Leading to severe dehydration and electrolyte imbalance.
  • Rapid Worsening of Symptoms: Suggesting progression to severe disease or complications.

Laboratory Tests

Laboratory confirmation is essential as clinical diagnosis is often unreliable.

• First-Line:

  • Complete Blood Count (CBC):
    • Typically shows leukopenia (low white blood cell count) and neutropenia.
    • Anemia may develop in prolonged illness or with gastrointestinal bleeding.
    • Thrombocytopenia can occur.
  • Blood Culture: Gold standard for diagnosis of acute typhoid fever.
    • Sensitivity: Varies but generally 50-70% in the first week of illness (highest when fever is highest), decreasing thereafter.
    • Procedure: At least 10-15 mL of blood for adults (2-5 mL for children) drawn before antibiotic administration and inoculated into appropriate blood culture bottles. Multiple samples increase yield.
    • Turnaround Time: Results typically available within 24-72 hours, but can take up to 7 days for slow-growing strains. Essential for antimicrobial susceptibility testing.
  • Liver Function Tests (LFTs): Mildly elevated transaminases (AST, ALT) are common, indicating hepatic involvement.
  • Electrolytes, Renal Function Tests: To assess hydration and kidney function, especially in patients with vomiting/diarrhea or severe illness.

• Confirmatory:

  • Bone Marrow Aspirate Culture: Most sensitive diagnostic test (90-95% sensitivity), often positive even after antibiotic therapy has started, or when blood cultures are negative. It is typically reserved for cases where blood cultures are negative but clinical suspicion remains high.
  • Stool Culture: Useful for identifying active shedding and chronic carriers.
    • Sensitivity: Lower than blood culture in acute illness (30-50%), but increases in the third week of illness as bacteria are shed.
    • Procedure: Serial stool samples (at least 3) are recommended due to intermittent shedding.
  • Urine Culture: Lower yield (5-10% positive) than blood or stool, primarily useful for detecting carriers who excrete bacteria in urine (e.g., due to Schistosoma haematobium co-infection).
  • Serological Tests (e.g., Widal Test):
    • Limitations: Detects antibodies (O and H agglutinins) against S. Typhi. Often has low sensitivity and specificity due to:
      • Cross-reactivity: With other Salmonella serovars or non-typhoidal febrile illnesses (e.g., malaria, dengue, relapsing fever).
      • Prior Infection/Vaccination: Positive results can persist for years, making interpretation difficult in endemic areas or vaccinated individuals.
      • Delayed Seroconversion: Antibodies may not appear until the second or third week of illness, limiting utility in early diagnosis.
    • Interpretation: A four-fold rise in antibody titer between acute and convalescent sera (taken 7-10 days apart) is more indicative, but not always practical. Single high titers are unreliable.
    • Recommendation: Not recommended by WHO or CDC for routine diagnosis of acute typhoid fever due to poor reliability.
  • Rapid Diagnostic Tests (RDTs):
    • Various RDTs targeting Vi antigen, LPS, or flagellar antigens exist (e.g., Tubex TF, Typhidot).
    • Limitations: Similar to Widal, sensitivity and specificity are variable. May be useful in resource-limited settings for screening, but a negative result does not rule out typhoid, and a positive result requires confirmation by culture. Not a substitute for culture.
  • Molecular Tests (PCR):
    • Detect S. Typhi DNA in blood, bone marrow, or stool.
    • Advantages: Can be faster than culture.
    • Limitations: High cost, lack of standardization, and inability to perform antimicrobial susceptibility testing. May detect non-viable organisms, making interpretation challenging. Not widely available for routine diagnostics in all settings.

• Monitoring:

  • Repeat Blood Cultures: Not routinely recommended to confirm eradication unless clinical response is poor or in cases of chronic carriage.
  • Stool Cultures: For detecting chronic carriers; typically, three consecutive negative stool cultures at least 48 hours apart after antibiotic completion confirm clearance in non-carriers.
  • CBC, LFTs, Electrolytes: Monitor for complications, response to treatment, and assess general health status.

Imaging

Imaging is not routinely used for diagnosing uncomplicated typhoid fever but may be helpful for assessing complications.

• Recommended:
  • Abdominal Ultrasound: Can show hepatosplenomegaly, gallbladder thickening, or distension (typhoid cholecystitis), or fluid in the peritoneal cavity suggestive of perforation.
  • Chest X-ray (CXR): Indicated if respiratory symptoms suggest pneumonia or acute respiratory distress syndrome (ARDS).
• Advanced:
  • CT Scan of Abdomen/Pelvis: If intestinal perforation, hemorrhage, or other severe abdominal complications (e.g., abscesses) are suspected, or to evaluate a chronic carrier's gallbladder.
  • CT/MRI of Brain: If severe neurological complications (e.g., encephalopathy, meningitis, cerebral abscess) are suspected.

Management

Timely initiation of appropriate antimicrobial therapy is crucial. Treatment decisions must consider local antimicrobial resistance patterns.

Acute Management

• Immediate:
  • Fluid Resuscitation: Initiate intravenous fluids (e.g., normal saline or Ringer's lactate) for patients with signs of dehydration, vomiting, or inability to take oral fluids.
  • Antimicrobial Therapy: Start empiric antibiotics promptly based on local resistance patterns, without waiting for culture results in suspected cases. Adjust therapy once susceptibility results are available.
• Stabilization:
  • Symptomatic Treatment:
    • Antipyretics: Paracetamol (acetaminophen) for fever management. NSAIDs should be used cautiously due to potential risk of gastrointestinal bleeding.
    • Nutritional Support: Encourage oral intake of soft, easily digestible foods. Intravenous nutrition may be necessary for severe cases or those with complications limiting oral intake.
    • Electrolyte Correction: Address any electrolyte imbalances resulting from vomiting, diarrhea, or poor intake.
• Emergency:
  • Management of Complications:
    • Intestinal Perforation: Requires immediate surgical intervention (laparotomy with primary repair or resection) and broad-spectrum antibiotics covering enteric flora.
    • Intestinal Hemorrhage: Requires fluid resuscitation, blood transfusions if severe, and consideration of surgical intervention if bleeding is uncontrolled.
    • Typhoid Encephalopathy: May require corticosteroids (e.g., dexamethasone) in severe cases, in addition to antibiotics.
    • Shock: Aggressive fluid resuscitation and vasopressors if needed.
  • Monitoring: Close monitoring of vital signs, fluid balance, and clinical status in hospitalized patients.

Chronic Management

• Pharmacological:
  • Antibiotics for Acute Infection:
    • Fluoroquinolones (e.g., Ciprofloxacin, Levofloxacin): Were historically first-line for sensitive strains.
      • Ciprofloxacin: Adults: 500 mg orally twice daily (BID) for 7-10 days, or 400 mg IV BID. Children: 15 mg/kg/day orally or IV divided BID for 7-10 days (use with caution in children due to theoretical cartilage concerns, but widely used and considered safe for short courses in practice when resistant strains are prevalent).
      • Levofloxacin: Adults: 500 mg orally or IV once daily (OD) for 7-10 days.
      • Resistance: Increasing resistance to fluoroquinolones (especially Nalidixic acid-resistant S. Typhi [NARST] and decreased susceptibility to ciprofloxacin [DSC]) is widespread, particularly in South Asia. If resistance is suspected or confirmed, alternatives are needed.
    • Azithromycin: Increasingly used as first-line, especially for fluoroquinolone-resistant strains.
      • Dosage: Adults: 500 mg orally once daily for 7 days. Children: 10-20 mg/kg/day orally for 7 days (max 1g/day).
      • Advantages: Good tissue penetration, safe in children and pregnancy, effective against MDR strains.
    • Third-Generation Cephalosporins (e.g., Ceftriaxone, Cefotaxime): Effective against susceptible strains, especially for severe illness or in children.
      • Ceftriaxone: Adults: 1-2 g IV once daily for 7-10 days. Children: 50-75 mg/kg IV once daily for 7-10 days (max 2g/day).
      • Limitations: Not effective for chronic carriers (poor gallbladder penetration). Increasing resistance reported.
    • Oral Cefixime: Adults: 400 mg orally once daily for 10-14 days. Children: 15 mg/kg/day orally for 10-14 days. Less effective than injectable cephalosporins for severe disease.
    • Carbapenems (e.g., Meropenem): Reserved for extensively drug-resistant (XDR) strains or severe complicated cases where other options have failed.
      • Meropenem: Adults: 1 g IV every 8 hours for 7-10 days.
    • Corticosteroids: Dexamethasone (3 mg/kg IV initially, then 1 mg/kg every 6 hours for 48 hours) is recommended for severe typhoid fever with altered mental status, stupor, coma, or shock.
  • Treatment for Chronic Carriers:
    • Difficult to eradicate. Often requires prolonged antibiotic courses.
    • First-line: Ciprofloxacin 500 mg BID for 4 weeks.
    • Alternatives: Amoxicillin 6 g/day or trimethoprim-sulfamethoxazole (TMP/SMX) 320/1600 mg/day for 6 weeks.
    • Cholecystectomy: May be necessary for chronic carriers with gallstones or failed medical therapy, as the gallbladder is a common site of persistent infection.
• Non-pharmacological:
  • Rest: Adequate rest during the acute phase.
  • Hydration: Maintain good hydration.
  • Nutritional Support: Gradual return to a regular diet. Avoid highly spicy or fibrous foods during recovery.
  • Hygiene: Strict hand hygiene, especially for food handlers, to prevent transmission.
• Monitoring:
  • Clinical Improvement: Fever resolution, improved mental status, reduction in abdominal symptoms.
  • Follow-up Cultures: Not routinely needed for all patients after treatment. However, in food handlers or healthcare workers, a series of negative stool cultures after treatment is required to ensure clearance and prevent transmission.
  • Monitoring for Chronic Carrier State: Repeat stool cultures (e.g., 3 consecutive negative cultures at least 48 hours apart, obtained one month after completing therapy) are crucial for individuals at high risk of chronic carriage (e.g., gallbladder abnormalities, age >60 years, female sex) and those in occupations that pose a risk for transmission (e.g., food handlers).

Treatment Algorithms

The choice of antibiotic depends on local antimicrobial resistance patterns and patient factors (severity, age, pregnancy).

• First-Line (Empiric, based on common resistance patterns):
  • Non-MDR/Non-XDR areas: Fluoroquinolones (Ciprofloxacin 500 mg BID for 7-10 days) or Azithromycin (500 mg OD for 7 days).
  • MDR (Multi-Drug Resistant) areas: Azithromycin (500 mg OD for 7 days) or Ceftriaxone (1-2g IV OD for 7-10 days).
  • Mild/Moderate Illness: Oral Azithromycin or oral Cefixime.
• Second-Line (for non-response or specific resistance):
  • If fluoroquinolone resistance (MDR) is suspected/confirmed: Switch to Azithromycin or Ceftriaxone.
  • If Ceftriaxone resistance (MDR/XDR) is suspected/confirmed: Switch to Azithromycin or Carbapenems (Meropenem 1g IV Q8H).
• Refractory Cases:
  • Verify Diagnosis: Reconfirm S. Typhi infection through culture (blood, bone marrow if needed) and obtain full antimicrobial susceptibility testing.
  • Re-evaluate Antibiotic Choice: Adjust based on susceptibility profile. Consider carbapenems for XDR strains.
  • Rule out Complications: Abscess formation, intestinal perforation, or other localized infections.
  • Surgical Intervention: For complications like perforation or for chronic carriers with cholelithiasis.
  • Corticosteroids: For severe toxic patients with neurological involvement (encephalopathy).
  • Consider Drug-Drug Interactions: Ensure appropriate dosing and absorption.

Complications

Complications occur in 10-15% of hospitalized patients, particularly with delayed diagnosis or treatment.

• Common:
  • Gastrointestinal Bleeding: Occurs in 10-20% of cases, often due to erosion of blood vessels in intestinal ulcers (especially in Peyer's patches).
  • Intestinal Perforation: The most serious complication, occurring in 1-3% of cases, typically in the third week of illness in the distal ileum, leading to peritonitis and sepsis. High mortality rate if untreated.
  • Relapse: Occurs in 5-10% of patients, usually within 2-3 weeks after cessation of therapy, often due to inadequate treatment or re-infection. Usually milder than the initial episode.
• Serious (Systemic):
  • Typhoid Encephalopathy: Altered mental status, delirium, stupor, coma, seizures.
  • Myocarditis: Inflammation of the heart muscle, leading to arrhythmias, heart failure.
  • Hepatitis/Cholecystitis: Severe hepatic dysfunction or inflammation of the gallbladder (may lead to chronic carriage).
  • Pneumonia/Bronchitis: Respiratory tract involvement.
  • Acute Cholecystitis: Can occur during acute illness or as a chronic carrier manifestation.
  • Disseminated Intravascular Coagulation (DIC): A rare but severe coagulopathy.
  • Acute Renal Failure: Due to severe sepsis or multi-organ dysfunction.
• Long-term:
  • Chronic Carrier State: 1-5% of patients (especially adult women with gallstones) can excrete S. Typhi for more than a year. These individuals are asymptomatic but are a significant source of infection in the community.

Prognosis

• Factors:
  • Timely Diagnosis and Treatment: Prompt and appropriate antibiotic therapy significantly improves outcomes.
  • Severity of Illness: Severe illness at presentation, especially with complications (perforation, encephalopathy), portends a worse prognosis.
  • Antimicrobial Resistance: Infection with drug-resistant strains (MDR, XDR) is associated with higher morbidity and mortality due to treatment failure or delayed effective therapy.
  • Host Factors: Age (very young and elderly), malnutrition, and immunocompromised status are associated with worse outcomes.
  • Nutritional Status: Malnourished children are at higher risk of complications and mortality.
• Survival:
  • With prompt and appropriate antibiotic treatment, the case-fatality rate for uncomplicated typhoid fever is less than 1%.
  • Without treatment, mortality rates can be as high as 10-30%.
  • Mortality increases significantly with complications, especially intestinal perforation (mortality can reach 30-50% even with surgery).
• Quality of Life:
  • Most patients make a full recovery without long-term sequelae if treated promptly.
  • However, the prolonged fever and debility can result in significant loss of productivity and educational days.
  • Recurrent infections or chronic carrier state can impact long-term quality of life and public health.

Prevention

Primary

• Vaccination: Highly recommended for travelers to endemic areas and individuals living in high-risk settings.
  • Ty21a (live-attenuated oral vaccine): Administered as 3-4 doses on alternate days. Efficacy ~50-80% for 5-7 years. Not for children <6 years, or immunocompromised.
  • Vi Capsular Polysaccharide (ViPS) vaccine (injectable): Single intramuscular dose. Efficacy ~50-80% for 2-3 years. Approved for children ≥2 years.
  • Typhoid Conjugate Vaccine (TCV - e.g., Vi-CRM197): Newer, more immunogenic, can be given to infants from 6 months of age, and confers longer-lasting immunity. Provides better efficacy and potentially herd immunity. Becoming preferred in endemic regions and for travelers.
• Safe Water and Sanitation:
  • "Boil it, cook it, peel it, or forget it": A common traveler's adage.
  • Drink bottled, boiled, or chemically treated water. Avoid ice.
  • Eat hot, well-cooked food. Avoid raw or undercooked meats, unpasteurized dairy, and raw fruits/vegetables unless peeled by the individual.
  • Proper disposal of human waste.
  • Improved municipal water treatment and sanitation infrastructure.
• Personal Hygiene:
  • Thorough handwashing with soap and water before preparing food or eating, and after using the toilet.
  • Avoid direct contact with sick individuals.

Secondary

• Early Diagnosis and Treatment: Prompt identification of cases and initiation of appropriate antibiotics to shorten the duration of illness, prevent complications, and reduce community transmission.
• Contact Tracing: Identify and educate close contacts of confirmed cases, especially household members.
• Health Education: Public awareness campaigns on hygiene, safe food/water practices, and symptoms of typhoid.

Tertiary

• Management of Chronic Carriers:
  • Identification of chronic carriers through stool cultures, particularly those in high-risk occupations (food handlers, healthcare workers).
  • Appropriate antibiotic treatment (e.g., prolonged ciprofloxacin) and, if necessary, cholecystectomy, to eliminate carriage.
  • Exclude carriers from food handling duties until clearance is confirmed by negative stool cultures.
• Prevention of Relapse: Ensure completion of the full antibiotic course.

Special Populations

• Pediatric:
  • Clinical Presentation: Children often have a milder, less typical course, sometimes presenting with diarrhea rather than constipation, and less frequently with rose spots or relative bradycardia. Risk of complications like intestinal perforation is higher in young children.
  • Diagnosis: Blood culture is still the gold standard.
  • Management:
    • Antibiotics: Azithromycin (10-20 mg/kg/day orally for 7 days) and third-generation cephalosporins (Ceftriaxone 50-75 mg/kg IV once daily) are generally preferred over fluoroquinolones due to concerns (though largely theoretical for short courses) about cartilage damage. Fluoroquinolones may be used if resistance to other agents is high and benefits outweigh risks.
    • Dosage: Strict adherence to weight-based dosing.
    • Complications: Monitor closely for dehydration, intestinal complications, and encephalopathy.
  • Prevention: TCV (Typhoid Conjugate Vaccine) is suitable for infants and young children, providing early protection.
• Geriatric:
  • Clinical Presentation: May have atypical or attenuated symptoms, delayed diagnosis, and higher risk of complications due to comorbidities and weakened immune systems. Fever may be lower, and confusion may be the predominant symptom.
  • Management: Higher risk of drug interactions and adverse effects from antibiotics. Careful assessment of comorbidities and renal/hepatic function before prescribing.
  • Prognosis: Increased mortality rate compared to younger adults.
• Pregnancy:
  • Clinical Presentation: Typhoid fever during pregnancy can increase the risk of maternal and fetal complications (e.g., spontaneous abortion, premature labor, low birth weight, stillbirth).
  • Management:
    • Antibiotics: Azithromycin (500 mg orally once daily for 7 days) and Ceftriaxone (1-2 g IV once daily for 7-10 days) are considered safe and effective first-line options. Fluoroquinolones are generally avoided due to theoretical fetal cartilage toxicity, but may be used if other options are unavailable or ineffective for severe/resistant infections.
    • Monitoring: Close monitoring for obstetric complications.
  • Prevention: Vaccination is generally not recommended during pregnancy unless the risk of exposure is very high, and the benefits outweigh potential risks (consult guidelines).
• Comorbidities:
  • Immunocompromised Patients (e.g., HIV, cancer, transplant recipients): At higher risk of severe disease, bacteremia, disseminated infection, and prolonged shedding. May require longer courses of antibiotics. Choice of antibiotics may be influenced by existing drug regimens and potential interactions.
  • Patients with Gallstones: Higher risk of developing chronic carriage due to S. Typhi biofilm formation on gallstones. May require cholecystectomy if carriage persists despite antibiotics.
  • Patients with Achlorhydria/Antacid Use: Increased susceptibility due to reduced gastric acid barrier.

Clinical Pearls

• Diagnostic:
  • "Don't Widal and Wait": The Widal test is notoriously unreliable and should not be used for definitive diagnosis of acute typhoid fever. It can lead to misdiagnosis, inappropriate treatment, and delayed effective therapy.
  • Blood Culture is King: Blood culture remains the gold standard for acute diagnosis. Obtain cultures before starting antibiotics whenever possible.
  • Bone Marrow Culture for Difficult Cases: Consider bone marrow culture for highly suspected cases with negative blood cultures, especially if antibiotics have been initiated.
  • Think Typhoid in Travelers: Any febrile illness in a traveler returning from an endemic region should prompt consideration of typhoid fever.
  • Rule out Malaria: In co-endemic areas, always rule out malaria, as presentations can overlap.
• Treatment:
  • Know Local Resistance: Consult local microbiology data and public health guidelines for current antimicrobial resistance patterns (MDR, XDR) to guide empiric therapy. This is crucial for selecting effective antibiotics.
  • Azithromycin for Resistance: Azithromycin is often a preferred first-line agent, particularly when fluoroquinolone resistance is prevalent or suspected, and is safe in children and pregnancy.
  • Corticosteroids for Severity: Dexamethasone is critical for severe typhoid with neurological compromise or shock, in addition to antibiotics.
  • Watch for Complications: Be vigilant for intestinal bleeding (melena, hematochezia, falling hemoglobin) and perforation (sudden severe abdominal pain, guarding, rigidity) as they require urgent intervention.
• Pitfalls:
  • Misreliance on Widal Test: A common and dangerous pitfall leading to diagnostic delays and inappropriate treatment.
  • Inadequate Course of Antibiotics: Leading to relapse or development of chronic carriage. Always complete the prescribed course.
  • Ignoring Public Health Implications: Failure to identify and manage chronic carriers, especially food handlers, poses a significant risk for ongoing transmission.
  • Delayed Surgical Intervention: In cases of perforation, delayed surgery drastically increases mortality.

Recent Updates

• Guidelines:
  • WHO Guidelines on Typhoid Vaccines (2018): Emphasize the increasing role of Typhoid Conjugate Vaccines (TCVs) for routine immunization in endemic areas and for travelers, recommending their preferential use over older vaccines due to better efficacy, suitability for infants, and potential for herd protection.
  • IDSA Guidelines for the Diagnosis and Management of Infectious Diarrhea (2017): Reiterate the unreliability of serological tests like Widal for acute diagnosis and recommend culture-based methods.
  • CDC Yellow Book (Travel Health): Regularly updated recommendations for typhoid vaccination for travelers based on destination and risk.
• Evidence:
  • Emergence of XDR S. Typhi: The spread of extensively drug-resistant (XDR) S. Typhi, particularly a strain resistant to fluoroquinolones, third-generation cephalosporins, and azithromycin (leaving only carbapenems or polymyxins as options), originating in Pakistan and spreading globally, is a major concern. This highlights the urgent need for new antibiotics and widespread TCV use.
  • TCV Efficacy Trials: Recent large-scale effectiveness studies in endemic countries confirm the high efficacy and safety of TCVs in preventing typhoid fever in real-world settings.
  • Global Burden of Disease Studies: Continued refinement of estimates for typhoid fever incidence and mortality, indicating a significant but often under-recognized burden, especially in young children and in settings with poor infrastructure.
• Controversies:
  • Optimal Management of XDR Typhoid: As options narrow, debates continue regarding the optimal duration and combination therapy for XDR strains, and the role of novel agents.
  • Role of Routine TCV Vaccination: While TCVs are transformative, discussions persist on the best strategies for widespread implementation and integration into national immunization programs in highly endemic countries, given cost and logistical challenges.
  • Ciprofloxacin in Children: While general guidelines still advise caution, practical clinical experience and some studies suggest short courses of ciprofloxacin are safe in children when needed for drug-resistant typhoid, leading to ongoing debate about its risk-benefit profile in specific scenarios.

Key References

• Guidelines:
  • World Health Organization (WHO). Typhoid vaccines: WHO position paper – March 2018. Weekly Epidemiological Record, 2018, 93(13): 153-172.
  • Centers for Disease Control and Prevention (CDC). Yellow Book 2024: Health Information for International Travel. (Chapters on Typhoid & Paratyphoid Fever).
  • Infectious Diseases Society of America (IDSA). Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea (2017). (Section on Enteric Fever).
  • National Institute for Health and Care Excellence (NICE). Guidelines related to infections, where applicable.
• Studies:
  • Qamar, F. N., et al. (2019). Efficacy of a Typbar-TCV® Typhoid Conjugate Vaccine in Children Aged 9 Months to 16 Years in Urban Sindh, Pakistan: A Phase 3, Single-Blind, Randomised Controlled Trial. The Lancet Infectious Diseases, 19(11): 1205-1215. (Landmark TCV efficacy study).
  • Klemm, E. J., et al. (2018). Emergence of an Extensively Drug-Resistant Salmonella Typhi Clone in Pakistan. The New England Journal of Medicine, 379(12): 1123-1132. (Key study on XDR emergence).
• Reviews:
  • Crump, J. A., & Heyderman, R. S. (2015). A systematic review of the global epidemiology of typhoid fever. Tropical Medicine & International Health, 20(2): 102-108.
  • Parry, C. M., et al. (2018). Typhoid fever. Nature Reviews Disease Primers, 4(1): 1-19. (Comprehensive review of pathophysiology, diagnosis, and treatment).
  • Long, B. R., et al. (2020). Typhoid Fever: An Updated Review of Diagnostic and Treatment Approaches. Current Infectious Disease Reports, 22(1): 2.